SLC5A1
ENSG00000100170
Target class
Transporter
Chromosome
22
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- Yes
- Target name
- SLC5A1
- Gene name
- Solute carrier family 5 member 1
- Gene symbol
- SLC5A1
- Previous gene symbols
- SGLT1
- Protein name
- Sodium/glucose cotransporter 1 (Na(+)/glucose cotransporter 1) (High affinity sodium-glucose cotransporter) (Solute carrier family 5 member 1)
- D22S675
- NAGT
- SGLT-1
- Gene biotype
- Protein coding
- Gene family
- Solute carrier family 5
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 15
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 97.91
- Tissue specificity (Gini)
- 0.877
- Tissue specificity (tau)
- 0.965
- KEGG gene identifiers
- hsa:6523
- Protein interaction confidence
- 0.8277
- Protein interaction partners
- 20
- R-HSA-189200
- R-HSA-5656364
- R-HSA-8981373
- End position
- 32113029
- Start position
- 32043050
- Chromosome
- 22
- Strand
- Forward
- Apical cell membrane
- Multi-pass membrane protein .
- Plasma membrane
- PubMed 26945065
- PubMed 34880492
- PubMed 37217492
- Tissue specificity (tau)
- 0.96545
- Expression inequality (Gini)
- 0.876684
Expression in transcripts per million
- Small Intestine - Terminal Ileum
- 97.91
- Heart - Left Ventricle
- 45.42
- Heart - Atrial Appendage
- 24.01
- Minor Salivary Gland
- 23.09
- Skin - Sun Exposed (Lower leg)
- 22.37
Expression in transcripts per million
- Small Intestine - Terminal Ileum97.91
- Heart - Left Ventricle45.42
- Heart - Atrial Appendage24.01
- Minor Salivary Gland23.09
- Skin - Sun Exposed (Lower leg)22.37
- Skin - Not Sun Exposed (Suprapubic)22.17
- Vagina9.09
- Colon - Transverse6.36
- Testis6.14
- Esophagus - Mucosa6.02
- Spleen2.91
- Prostate2.72
- Pituitary1.82
- Lung1.29
- Liver1.04
- Breast - Mammary Tissue0.86
- Pancreas0.71
- Stomach0.56
- Kidney - Medulla0.45
- Fallopian Tube0.41
- Kidney - Cortex0.21
- Colon - Sigmoid0.12
- Brain - Cortex0.1
- Brain - Frontal Cortex (BA9)0.1
- Brain - Anterior cingulate cortex (BA24)0.1
And 29 more, listed on the interactive page.
- GO:0000017
- GO:0035377
- GO:0098708
- GO:0098719
- GO:0106001
- GO:0150104
- GO:1902476
- GO:1904659
- GO:0005769
- GO:0005886
- GO:0016324
- GO:0048471
- GO:0070062
- GO:0097708
- GO:0005372
- GO:0005412
- GO:0005515
- GO:0015151
- GO:0015371
- GO:0055056
Related records
Trials (1,387)
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
- "Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"
- 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension
- 4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes
- 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
- A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
- A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions
- A Biomarker-targeted Clinical Trial to Optimize Treatment for Patients With Chronic Kidney Disease
- A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients
- A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
Drugs (14)
- Bexagliflozin
- Canagliflozin
- Canagliflozin anhydrous
- Dapagliflozin
- Empagliflozin
- Enavogliflozin
- Ertugliflozin
- Ipragliflozin
- Licogliflozin Sodium/glucose cotransporter 1 inhibitor
- Mizagliflozin
- Sergliflozin etabonate
- Sotagliflozin Sodium/glucose cotransporter 1 inhibitor
- Tofogliflozin
- Tofogliflozin anhydrous